Day: March 25, 2022

NEW YORK, March 25, 2022 (GLOBE NEWSWIRE) — Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the fourth quarter and full-year ended December 31, 2021. Recent Business Highlights During and since the fourth quarter, Delcath:Reported updated positive phase 3 FOCUS trial results for HEPZATO™ Kit (melphalan hydrochloride for injection/hepatic delivery system) for the treatment of patients with unresectable liver-dominant metastatic ocular melanoma, including initial survival data analysis Confirmed guidance for the mid-year Class 2 resubmission of the NDA to FDA Resumed direct responsibility for sales, marketing, and distribution activities for the CHEMOSAT® Hepatic Delivery...

TORONTO, March 25, 2022 (GLOBE NEWSWIRE) — Marathon Gold Corporation (“Marathon” or the “Company”; TSX: MOZ) today announces its financial results for the fourth quarter and year ending December 31, 2021 and provides an update on the Company’s activities at the Valentine Gold Project (the “Project”) in the central region of Newfoundland and Labrador (“NL”). Fourth Quarter HighlightsAt December 31, 2021, the Company had cash and cash equivalents of $87.2 million, leaving it well positioned to execute on its permitting, development, and exploration activities at the Project; During the fourth quarter of 2021, a total of 19,497 metres of exploration drilling was completed in 73 holes primarily at the Berry, Victory and Sprite Deposits. In total during 2021, Marathon completed 74,004 metres of drilling, successfully completing its...

Entering 2022 well-positioned to execute on wellness strategy focused on Canadian B2B recreational cannabis and North American nutraceuticals TORONTO, March 25, 2022 (GLOBE NEWSWIRE) — Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: NXTTF), a health-tech company that leverages advancements in science and technology to build breakthrough companies that transform human wellness, today reported its financial results for year ended November 30, 2021. All financial figures are in Canadian dollars unless otherwise indicated. Fourth Quarter 2021 HighlightsWhile net revenue decreased 11% to $6.4 million in the fourth quarter ended November 30, 2021 (“Q4 2021”) (compared to $7.2 million in the same period last year (“Q4 2020”)), this was mainly due to declines in hardware sales in Europe and...

Global Phase 2b trial for eblasakimab in moderate-to-severe atopic dermatitis (AD) underway with topline data expected in the first half of 2023 New CMO appointed, adding senior global pharma experience to the leadership teamCompany maintains strong operating position with US$90.2 million in cash and cash equivalents as of December 31, 2021, runway through late 2023 Replays available for company-hosted A4 KOL series on AD landscape; next event to be held in the second quarterMENLO PARK, Calif. and SINGAPORE, March 25, 2022 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the fourth quarter and full year ended December 31, 2021, and provided an update...

BALA CYNWYD, Pa., March 25, 2022 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its full year 2021 operating and financial results. “The past year was highlighted by our first clinical data readouts, which demonstrated the potential of CTI-1601 to address the root cause of Friedreich’s ataxia by increasing frataxin levels in patients,” said Carole Ben-Maimon, MD, President and Chief Executive Officer of Larimar. “With these important proof-of-concept data in hand, we continue to work expeditiously to identify the best path forward through the resolution of CTI-1601’s clinical hold. Our commitment to furthering CTI-1601’s development remains steadfast, and the urgent unmet needs of patients...

OXFORD, United Kingdom, March 25, 2022 (GLOBE NEWSWIRE) — Vaccitech plc (NASDAQ: VACC) today announced its financial results for the full year ended December 31, 2021 and provided an overview of the Company’s recent corporate developments. Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. “2021 was a pivotal year for Vaccitech during which we achieved a number of strategic, operational, and financial objectives, advanced multiple immunotherapeutic and prophylactic candidates in clinical development and strengthened and expanded our T cell activating discovery engine platform via the acquisition of Avidea Technologies,” commented Bill Enright, Vaccitech’s CEO. “All of this progress...

– Completed successful initial public offering, raising $98 million in gross proceeds – – Initiated VGL101 Phase 1 trial; Phase 2 trial in ALSP patients expected to initiate in 2H 2022 – – Initiated IND-enabling studies in the small molecule Alzheimer’s disease TREM2 agonist program – – Advanced understanding and awareness of ALSP through publication of review article and launch of global patient registry – CAMBRIDGE, Mass., March 25, 2022 (GLOBE NEWSWIRE) — Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on recent business highlights. “This...